Dr. Mogal on the Incidence and Prognosis of Peritoneal Carcinomatosis in CRC

Video

In Partnership With:

Harveshp D. Mogal, MD, MS, FACS, DABS, FSSO, discusses the incidence and prognosis of peritoneal carcinomatosis in colorectal cancer.

Harveshp D. Mogal, MD, MS, FACS, DABS, FSSO, physician, Seattle Cancer Care Alliance, associate professor, Department of Surgery, University of Washington (UW) School of Medicine, program director, Regional Cancer Therapies, UW Medicine, discusses the incidence and prognosis of peritoneal carcinomatosis in colorectal cancer (CRC).

Isolated peritoneal carcinomatosis is a challenging complication that occurs in approximately 10% of patients with CRC, Mogal says. Patients with peritoneal disease have inherently poor biology, which makes them difficult to treat. Moreover, patients with peritoneal carcinomatosis have a worse overall prognosis compared with patients with isolated lung or liver metastases, as well as patients with combined lung and liver metastases.

Additionally, systemic therapies that are effective in treating patients with isolated lung or liver metastases are not as effective in patients with peritoneal disease. The median survival with modern chemotherapy is approximately 18 months in patients with peritoneal disease. The addition of sequential targeted therapy to chemotherapy can extend survival to around 29 months, but more effective systemic agents are needed for this disease subgroup, Mogal concludes.

Related Videos
Chul Kim, MD, MPH
Neil D. Gross, MD, FACS
Dae Won Kim, MD, Gastrointestinal Oncology Program, Moffitt Cancer Center
Muhamad Alhaj Moustafa, MD, MS, hematologist, medical oncologist, Departments of Hematology and Oncology (Medical), Mayo Clinic
Reshma Jagsi, MD, DPhil, Emory University
Chandler H. Park, MD, FACP, Norton Health
A panel of 6 experts on colorectal cancer
A panel of 6 experts on colorectal cancer
Salman R. Punekar, MD, Mayo Clinic
Michael J. Overman, MD, The University of Texas MD Anderson Cancer Center,